phenyl-n-tert-butylnitrone has been researched along with Syndrome in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Durand, G; Geromel, V; Ouari, O; Polidori, A; Pucci, B; Rustin, P; Tordo, P | 1 |
Blazar, BR; Drobyski, WR; Gendelman, M; Halligan, N; Komorowski, R; Logan, B; Murphy, WJ; Pritchard, KA | 1 |
2 other study(ies) available for phenyl-n-tert-butylnitrone and Syndrome
Article | Year |
---|---|
Synthesis and preliminary biological evaluations of ionic and nonionic amphiphilic alpha-phenyl-N-tert-butylnitrone derivatives.
Topics: Adenosine Triphosphatases; Ataxia; Cell Membrane Permeability; Cell Survival; Cells, Cultured; Cyclic N-Oxides; Electron Spin Resonance Spectroscopy; Fibroblasts; Free Radical Scavengers; Humans; Hydrophobic and Hydrophilic Interactions; Mitochondrial Myopathies; Mutation; Nitrogen Oxides; Reactive Oxygen Species; Retinitis Pigmentosa; Structure-Activity Relationship; Syndrome | 2003 |
Alpha phenyl-tert-butyl nitrone (PBN) protects syngeneic marrow transplant recipients from the lethal cytokine syndrome occurring after agonistic CD40 antibody administration.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow Transplantation; CD40 Antigens; Cyclic N-Oxides; Cytokines; Lymphoma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Nitrogen Oxides; Survival Rate; Syndrome; Transplantation | 2005 |